Resources>Blog>VHH Antibodies

VHH Antibodies

Biointron 2024-01-20 Read time: 2 mins
VHH.jpg
Image credit: DOI: 10.1177/1535370219881129

Antibodies are essential tools in modern medicine and research, but not all antibodies are the same. VHH antibodies, also known as single-domain antibodies or nanobodies, are a type of antibody that offers several advantages over conventional antibodies. 

VHH antibodies are derived from the immune system of camelids, which produce antibodies that are much smaller than those produced by humans or mice. VHH antibodies consist of a single domain, or variable region, that is capable of binding to specific antigens. This makes them ideal for a wide range of applications, including diagnostic tests, therapeutics, and research tools. 

One key advantage of VHH antibodies is their small size. This allows them to penetrate tissues more effectively than larger antibodies, making them useful for targeting diseases that are difficult to reach with conventional therapies. Additionally, VHH antibodies are highly stable and can withstand harsh conditions, such as high temperatures or acidic environments, which makes them useful for a range of diagnostic and therapeutic applications. 

At Biointron, we specialize in the production of high-quality recombinant VHH antibodies for research and diagnostic purposes. Our team of experts uses state-of-the-art technologies to generate VHH antibodies that are highly specific and sensitive to their target antigens. Whether you need custom VHH antibody production or off-the-shelf options, we have the expertise to deliver the right solution for your needs. 

To learn more about our VHH antibody services, visit our website or contact us today. 

Recommended Articles
Biointron Announces RushData Launch Promotion for High-Throughput Antibody Characterization

Biointron announces limited-time RushData launch pricing for high-throughput ant……

Sep 03, 2026
Roundup of Antibody Biotech Deals in August 2026

August 2026 brought another mix of acquisitions, licensing agreements, strategic……

Sep 01, 2026
Understanding Single-Cell Droplet Technology in High-Throughput Antibody Screening

Antibody discovery often begins with a highly diverse population of B cells, onl……

Aug 31, 2026
Beyond Fast Expression: Scaling Antibody Validation to Thousands of Candidates

As larger candidate panels move from computational design into the laboratory, a……

Aug 28, 2026

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.